Addition of structure-to-name conversion toolkit will enhance chemical compound searching and improve productivity for researchers using Symyx applications
In an extension of its strategic partnership, Symyx Technologies plans to integrate OpenEye's Lexichem structure-name converter software with Symyx Draw and the soon-to-be-released Symyx Isentris 3.1 informatics system.
This integration will enhance and accelerate chemical compound searching by enabling chemists to generate structures for query or other purposes simply by providing chemical names rather than drawing the structures.
This time-saving capability initially will be incorporated into the upcoming release of the Symyx Draw structure editor.
"OpenEye products are complementary with Symyx solutions and by working together we will provide our customers with best-of-breed functionality," said Trevor Heritage, president of Symyx Software.
"This partnership creates greater flexibility within discovery workflows through improved efficiency in converting chemical names to chemical structures and vice versa.
"We look forward to a long-standing relationship with our colleagues at OpenEye Scientific Software".
"With Symyx, OpenEye's outstanding cheminformatics will gain a larger audience," said Matthew Stahl, senior vice president and head of strategic development at OpenEye Scientific Software.
"The breadth of Symyx software and its diverse customer base presents us with an outstanding opportunity to further temper our software".
As part of a continued programme to extend the range of files supported by Symyx Draw software to include popular chemical structure formats, Symyx will incorporate file converters from OpenEye's OEChem programming library for chemistry and cheminformatics into Symyx Draw.
This integration will enable Symyx Draw to read and write ChemDraw (CDX), canonical Smiles and a number of other file formats.
As part of this agreement, Prous Science, part of the scientific business of Thomson Reuters, and Symyx are extending to OpenEye access to the MDDR database, the leading bioactivity database jointly produced by Symyx and the scientific business of Thomson Reuters, for use in validating OpenEye's various scientific algorithms.
OpenEye will also be able to validate their models against the well-known Symyx Comprehensive Medicinal Chemistry database (Elsevier).
